227 related articles for article (PubMed ID: 29439147)
21. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
[TBL] [Abstract][Full Text] [Related]
22. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
[TBL] [Abstract][Full Text] [Related]
23. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study.
Skyler JS; Fonseca VA; Segal KR; Rosenstock J;
Diabetes Care; 2015 Sep; 38(9):1742-9. PubMed ID: 26153271
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
Proietto J; Malloy J; Zhuang D; Arya M; Cohen ND; de Looze FJ; Gilfillan C; Griffin P; Hall S; Nathow T; Oldfield GS; O'Neal DN; Roberts A; Stuckey BGA; Yue D; Taylor K; Kim D
Diabetologia; 2018 Sep; 61(9):1918-1922. PubMed ID: 29992370
[TBL] [Abstract][Full Text] [Related]
26. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
Frias JP; Choi J; Rosenstock J; Popescu L; Niemoeller E; Muehlen-Bartmer I; Baek S
Diabetes Care; 2022 Jul; 45(7):1592-1600. PubMed ID: 35671039
[TBL] [Abstract][Full Text] [Related]
28. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
Jacob S; Rabbia M; Meier MK; Hauptman J
Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
[TBL] [Abstract][Full Text] [Related]
29. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
Allas S; Delale T; Ngo N; Julien M; Sahakian P; Ritter J; Abribat T; van der Lely AJ
Diabetes Obes Metab; 2016 Sep; 18(9):868-74. PubMed ID: 27063928
[TBL] [Abstract][Full Text] [Related]
30. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.
Hermann LS; Scherstén B; Bitzén PO; Kjellström T; Lindgärde F; Melander A
Diabetes Care; 1994 Oct; 17(10):1100-9. PubMed ID: 7821128
[TBL] [Abstract][Full Text] [Related]
32. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP; Corbalan R; Hamm C; Kaplan L; Nicolau JC; Ophuis TO; Ray KK; Ruda M; Spinar J; Patel T; Miao W; Perdomo C; Francis B; Dhadda S; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
Lancet; 2018 Nov; 392(10161):2269-2279. PubMed ID: 30293771
[TBL] [Abstract][Full Text] [Related]
33. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Nahra R; Wang T; Gadde KM; Oscarsson J; Stumvoll M; Jermutus L; Hirshberg B; Ambery P
Diabetes Care; 2021 Jun; 44(6):1433-1442. PubMed ID: 34016612
[TBL] [Abstract][Full Text] [Related]
34. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
Elkind-Hirsch KE; Shaler D; Harris R
J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial.
Safarpour P; Daneshi-Maskooni M; Vafa M; Nourbakhsh M; Janani L; Maddah M; Amiri FS; Mohammadi F; Sadeghi H
BMC Fam Pract; 2020 Feb; 21(1):26. PubMed ID: 32033527
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Swarbrick MM; Havel PJ; Levin AA; Bremer AA; Stanhope KL; Butler M; Booten SL; Graham JL; McKay RA; Murray SF; Watts LM; Monia BP; Bhanot S
Endocrinology; 2009 Apr; 150(4):1670-9. PubMed ID: 19164474
[TBL] [Abstract][Full Text] [Related]
37. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
Hollander P; Maggs DG; Ruggles JA; Fineman M; Shen L; Kolterman OG; Weyer C
Obes Res; 2004 Apr; 12(4):661-8. PubMed ID: 15090634
[TBL] [Abstract][Full Text] [Related]
38. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
[TBL] [Abstract][Full Text] [Related]
39. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.
Nwosu BU; Maranda L; Cullen K; Greenman L; Fleshman J; McShea N; Barton BA; Lee MM
PLoS One; 2015; 10(9):e0137525. PubMed ID: 26367281
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA; Diaz Soto G; Izaola O; Romero E
J Diabetes Complications; 2015; 29(4):595-8. PubMed ID: 25825013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
